Biotech Startups

Seonix develops a genetic risk score to identify individuals at elevated risk of glaucoma, serving eye health professionals, patients, and researchers. The company uses large-scale genetic datasets and advanced techniques for clinical risk prediction to help prevent vision loss.

1 investor

Septest develops rapid point-of-need diagnostic tests for detecting infections and inflammation, including its multi-marker TRISEP test aimed at pre-hospital and community triage. The tools are intended for frontline healthcare professionals to speed sepsis detection and reduce antimicrobial resistance, with a focus on accessibility including in low- and middle-income countries.

1 investor

SeqCenter provides DNA sequencing services with an emphasis on data security and biosecurity for research organizations. The company operates U.S.-based infrastructure with secure data handling, chain-of-custody tracking, and encrypted delivery methods.

1 investor

SEQENS is a global supplier of pharmaceutical solutions and specialty ingredients serving health, personal care, and specialty ingredient customers. The company operates an R&D platform and emphasizes sustainability and corporate social responsibility across its operations.

1 investor

Sequential provides an in-house, end-to-end service for testing next-generation ingredients, covering study design, participant recruitment, laboratory analysis, and data interpretation. It translates microbial and molecular data into clinical insights that help companies validate product efficacy.

1 investor

SeraGene Therapeutics is a pre-clinical stage biotech company developing RNA (siRNA) and nanomedicine-based therapies for coagulation disorders, including rare bleeding disorders, platelet dysfunction, and thrombotic disorders. It aims to provide long-lasting, low-burden prophylactic treatments for patients living with chronic coagulation conditions.

1 investor

Serán is a contract development and manufacturing organization (CDMO) that provides drug formulation, development, and manufacturing services to pharmaceutical companies. The company specializes in process engineering, scaleup, and commercial manufacturing of solid dosage forms and advanced pharmaceutical technologies.

1 investor

SERB is a pharmaceutical company specializing in rare diseases and emergency medicine, with a portfolio of 70+ medicines including antidotes for chemical, biological, radiological and nuclear threats. The company serves hospitals, healthcare systems, first responders, and patients with rare conditions in oncology, neurology, and metabolic disorders across 100+ countries.

1 investor

SERDA Therapeutics is a clinical-stage biopharmaceutical company developing a prescription wound debridement therapy that uses a proprietary proteolytic enzyme to selectively digest necrotic tissue and eschar. Its lead candidate, SN514, targets burn wounds and chronic ulcers such as diabetic foot and venous leg ulcers.

1 investor

Serenatis Bio develops small-molecule drugs targeting glutamate and dopamine pathways to treat obsessive-compulsive disorder, a mental health condition with limited effective therapeutic options. The company's pipeline includes three novel candidates designed to work faster and with fewer side effects than existing medications.

1 investor

Serentrix is a biotech company developing targeted small-molecule therapies for pain relief that aim to avoid the addiction risks associated with existing painkillers.

1 investor

Serina Therapeutics is a clinical-stage biotechnology company developing its POZ Platform, a polymer technology ("POZylation") that modifies proven small molecule drugs to enable controlled, sustained release with fewer side effects. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease, and the platform is also applied to CNS indications and RNA medicines.

1 investor

Serotiny designs cell therapies using custom software and lab techniques that allow it to design and test up to 10,000 therapeutic genes at once, aiming to speed up the discovery of treatments for cancers such as multiple myeloma, prostate cancer and lung cancer. The San Francisco-based company works upstream in the cell and gene therapy discovery process and was acquired by Johnson & Johnson.

1 investor

Seroxo is a biotech company developing technology in the areas of immunology, cancer, and infectious disease, supported by a clinical advisory board of specialists. The company is associated with the University of Oxford research community.

1 investor

Serum Institute of India (SII) develops and manufactures vaccines, including candidates for tuberculosis and Bundibugyo ebolavirus, working with partners such as the Oxford Vaccine Group and the Gates Medical Research Institute. It operates in the biotech and healthcare industry with a focus on infectious-disease immunization.

1 investor

SetBone Medical develops solutions for spinal care and orthopedic applications. The company is advised by leading spine surgeons and orthopedic specialists.

1 investor

SEVO Bioscience engineers microalgae strains that produce antigens to prevent viral and bacterial diseases in farmed fish, delivered as an oral vaccine through direct feeding rather than injection. It serves aquaculture operations, aiming to reduce handling stress and ecosystem impact across the production cycle from hatchery to harvest.

1 investor

Seyitler Kimya is a chemical company operating in the healthcare sector, developing and manufacturing products that it exports regularly to 17 countries across the Middle East, Africa, Turkic republics, Europe, and the Americas. The company conducts R&D through university-industry collaborations, a technopark presence, and TÜBİTAK projects.

1 investor

SEYSARA is a prescription medication with a patient co-pay assistance program (Almirall Advantage) that offers savings on retail and network pharmacy purchases. The page is a manufacturer's patient savings/co-pay support site for people with private health insurance.

1 investor

Shaddari offers an AI system that predicts whether existing vaccines can neutralize a newly isolated virus variant using only its genetic code, returning results quickly instead of through weeks of lab testing. It is aimed at public and private labs working in precision medicine.

1 investor

Shanton Pharma is a clinical-stage biotech company developing drugs for gout, hyperuricemia, and pruritus. It focuses on researching and commercializing therapies for these conditions to serve patients and medical communities.

1 investor

Shape Biopharmaceuticals develops innovative immunotherapeutic drugs and vaccines using synthetic vaccine technology and bio-nanotechnology for clinical-stage applications. The company serves the biopharmaceutical industry with next-generation therapeutic solutions.

1 investor

Shared-X operates multiple subsidiaries focused on agribusiness and food sectors, including iQBiotech (biostimulants and biopesticides), Nampi Foods (consumer packaged goods), and Bananica (regenerative agriculture and specialty crop export). The company serves food and agriculture companies globally with sustainable and innovative agricultural solutions.

1 investor

Sharp Therapeutics develops a small molecule drug platform designed to treat genetic diseases more affordably and quickly than current biologics and gene therapies. The company targets patients and payors seeking faster, scalable alternatives to existing genetic disease treatments.

1 investor